Four peptides don't belong in one benefit column.
These four peptides aren't competing to do the same job. We put them beside each other to see what was tested. Picking a winner would hide the most useful differences.
Give each compound its own question
Ipamorelin and retatrutide both act on receptors, proteins that receive signals. Ipamorelin research follows growth hormone release. Retatrutide research looks at three hormone receptors: GIP, GLP-1 and glucagon. They aren't alternatives just because both involve signals.
Thymosin alpha-1 research explores immune activity. BPC-157 experiments involve blood-vessel growth, with exact targets less settled. We don't give all four explanations equal certainty just to fill a tidy table.
| Compound | Biological question | Human evidence |
|---|---|---|
| Thymosin alpha-1 | Does an immune effect help people survive sepsis? | A large trial found no clear improvement in survival at 28 days. |
| Ipamorelin | Does a hormone signal help bowel recovery? | The surgery trial missed its main goal. |
| BPC-157 | Do experimental repair findings hold up in people? | Small human reports leave healing and safety open. |
| Retatrutide | What happens when three hormone receptors are activated? | An obesity trial measured weight loss and side effects. |
Human study sounds like one thing. The table hides how many different jobs those studies do.
Human research can mean very different things
BPC-157's two-person pilot watched short-term safety after an infusion into a vein. The ipamorelin volunteer study measured a growth hormone response. Neither was a test of whether an injury healed faster or someone slept better.
Retatrutide's obesity trial measured weight changes and side effects. Thymosin alpha-1's sepsis trial measured survival at 28 days and found no clear benefit. That study declared manufacturer support and financial ties among authors. Different illnesses and outcomes prevent a fair benefit ranking.
The point of comparing is to get a clearer question, not a peptide shopping list.
Three checks that travel well
First, what was directly observed? A receptor interaction, a blood-test change and a difference in daily health aren't interchangeable. The word works is doing too much if the explanation never says which one it means.
Second, what wasn't tested? A hormone measurement can't supply a sleep result. Two adults without reported side effects can't settle long-term safety. The missing answers matter.
Third, what does access actually mean here? As of September 2026, none of these four has FDA drug approval. FDA distinguishes withdrawn compounding nominations from ipamorelin acetate's 503B Category 2 listing. Retatrutide has a separate compounding restriction. Their situations aren't identical.
Each article follows its own compound, with safety cautions beside the interesting findings. Your medical history belongs in a conversation with a licensed clinician. A study summary is only part of that picture.